Giripladib

Giripladib (PLA-695) is a indole-based inhibitor of cytosolic phospholipase A2 (cPLA2) . Giripladib can be used for osteoarthritis and breast cancer research[1][2].

Product Specifications

CAS Number

[865200-20-0]

Product Name Alternative

PLA-695

UNSPSC

12352005

Target

Phospholipase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/giripladib.html

Purity

99.68

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(CCCC2=C(CCNS(=O)(CC3=C(C(F)(F)F)C=CC=C3)=O)N(C(C4=CC=CC=C4)C5=CC=CC=C5)C6=C2C=C(C=C6)Cl)C=C1)O

Molecular Formula

C41H36ClF3N2O4S

Molecular Weight

745.25

References & Citations

[1]Kokotos G, et al. Inhibition of group IVA cytosolic phospholipase A2 by thiazolyl ketones in vitro, ex vivo, and in vivo. J Med Chem. 2014 Sep 25;57 (18) :7523-35.|[2]Liu S, et al. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties. J Hematol Oncol. 2021 Oct 29;14 (1) :178.